Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

he quarter ended September 30, 2010.  After adjusting for certain items as further detailed below, adjusted EBITDA was $446.9 million for the current three-month period and $368.1 million for the comparable prior year period, representing a 21% increase.  

Cash provided by operating activities, excluding certain items, was $378.1 million for the three months ended September 30, 2011.  The excluded items consist of a payment of $60.4 million to Merck KGaA as reimbursement for the tax savings generated through the settlement of indemnified litigation, and a net $34.7 million reversal of deferred revenue. On a GAAP basis, cash provided by operating activities was $283.0 million.For the nine months ended September 30, 2011, Mylan reported total revenues of $4.60 billion compared to $4.02 billion in the comparable prior year period, representing an increase of $582.6 million, or 14.5%   Revenues were favorably impacted by the effect of foreign currency translation, generally reflecting a weaker U.S. dollar as compared to the currencies in other major markets in which Mylan operates. Translating third party net revenues at prior year exchange rates would have resulted in year-over-year growth in third party net revenues excluding foreign currency of $459 million, or approximately 12%.

Other revenues from third parties for the nine months ended September 30, 2011, were $19.4 million compared to $36.4 million in the comparable prior year period, a decrease of $17.0 million.  

Generics third party net sales were $4.14 billion for the nine months ended September 30, 2011, compared to $3.63 billion in the comparable prior year period.

Third party net sales from North America were $2.12 billion for the nine months ended September 30, 2011, compared to $1.71 billion for the comparable prior year period, representing an increase of $406.5 million, or 23.7%. The increase in third party revenues was principally due to sales of ne
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... June 29, 2015 , ... ... of around 19% during the forecast period (2015 to 2020). The market is ... in government and corporate funding for R&D. However, lack of adequate healthcare and ...
(Date:6/29/2015)... , June 29, 2015  Neuralstem, Inc. (NYSE MKT: ... to develop small molecule and cell therapy treatments for ... been approved for listing on the NASDAQ Capital Market ... continue to trade on the NYSE MKT until the ... NASDAQ Capital Market is expected to commence on July ...
(Date:6/29/2015)... 29, 2015   For the seventh year running, Across ... their overall digital maturity called the Multichannel Maturometer ... are not maturing fast enough. While it,s true that ... ways overall and customers are increasingly "digital natives", pharma ... customer engagement.  ...
(Date:6/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... all nominees listed in the management information circular ... 2015 Annual Meeting of Shareholders, held earlier today, ... the following 5 nominees proposed by management were ... until the Company,s next Annual Meeting of Shareholders ...
Breaking Biology Technology:Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") today ... 31, 2007. All results are in U.S.,dollars and prepared ... ended December 31, 2007, was $20.3 million or,$1.04 per ... $2.38,per basic and diluted share in 2006. The substantial ...
... PharmAthene, Inc.,(Amex: PIP ) a biodefense ... announced today that David P. Wright,President and Chief ... and Company 28th Annual Health Care Conference in ... The presentation is scheduled to take place in,the ...
... Elekta Neuromag(R), the,world-leading equipment for non-invasive measurement ... been ordered by,Froedtert Memorial Lutheran Hospital., ... in the western suburbs of Milwaukee, Froedtert ... quality of life in Wisconsin and Northern,Illinois ...
Cached Biology Technology:Oncothyreon reports full year and fourth quarter 2007 financial results 2Oncothyreon reports full year and fourth quarter 2007 financial results 3Oncothyreon reports full year and fourth quarter 2007 financial results 4Oncothyreon reports full year and fourth quarter 2007 financial results 5Oncothyreon reports full year and fourth quarter 2007 financial results 6Oncothyreon reports full year and fourth quarter 2007 financial results 7Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee 2Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee 3
(Date:6/17/2015)... HILDEN , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... neue STR-Testkits der Produktlinie Investigator ... DNA-Spuren in den Markt eingeführt. Die neuen Kits zur ...
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces that its leading ... to media at Digital Experience! @ NYC June 18th. ... of the latest innovation in technology to over 300 of ... held at the Metropolitan Pavilion in New York ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... BOZEMAN, Mont. -- Controlling Japanese B encephalitis ... brain-injuring virus needs mosquitoes and pigs to spread, government ... urban drainage ditches. They should keep industrial "piggeries" away ... from industrial disease are much more complex than that, ...
... populations in threatened forests are far more sensitive to ... new research. An analysis of monkeys living in ... factors, such as human activity, on species numbers is ... Researchers also found that the health of monkey ...
... breakthrough of a lifetime, turning discarded fruit peels and other ... University of Central Florida professor Henry Daniell has developed ... as orange peels and newspapers. His approach is greener and ... on cleaner fuel and his goal is to relegate ...
Cached Biology News:Environmental historian now tackles industrial disease in Japan 2Environmental historian now tackles industrial disease in Japan 3Environmental historian now tackles industrial disease in Japan 4Orange peels, newspapers may lead to cheaper, cleaner ethanol fuel 2
Please email us with project details and we will respond within 24 hours to your query!...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
Request Info...
Request Info...
Biology Products: